Skip to main content

Table 3 Causes of morbidity in the patient group

From: Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial

Variable

Standard treatment (n = 250)

Intensive treatment (n = 254)

P value†

Length of stay in ICU (days)

   

Median (Interquartile range)

6 (3 to 11)

6 (3 to 12)

0.351

Duration of ventilatory support (days)

   

Median (Interquartile range)

5 (2 to 9)

6 (2 to 10)

0.857

Ventilatory support (%)

238 (95.2)

238 (93.7)

0.476

Dopamine (%)

190 (76)

182 (71.7)

 

Dosage (μg/kg/minute) *‡

14.45 ± 8.97

14.85 ± 8.99

0.366

Norepinephrine (%)

68 (27.2)

55 (21.7)

 

Dosages (μg/kg/minute) *‡

0.36 ± 0.77

0.36 ± 0.56

0.993

Epinephrine (%)

44 (17.6)

46 (18.1)

 

Dosages (μg/kg/minute) *‡

0.34 ± 0.40

0.31 ± 0.59

0.613

Dobutamine (%)

9 (3.6)

14 (5.5)

 

Dosages (μg/kg/minute) *‡

4.97 ± 2.43

8.43 ± 6.48

0.060

Swan Ganz (%)

28 (11.2)

30 (11.8)

0.800

Renal impairment (%) §

25 (10)

32 (12.6)

0.357

Renal-replacement therapy (%)

33 (13)

27 (10.8)

0.447

Hydrocortisone (%)

66 (26.4)

67 (26.3)

0.996

Ventilator associated pneumonia (%)

55 (22)

43 (16.9)

0.15

Catheter-related infection (%)

9 (3.6)

6 (2.4)

0.414

Urinary infections (%)

11 (4.4)

13 (5.1)

0.705

Primary bacteraemia (%)

8 (3.2)

7 (2.8)

0.769

Treatment with antibiotics for ≥ 8 days (%)

183 (73.2)

186(73.2)

0.994

Red-cell transfusions

   

   Patients requiring transfusions (%)

91 (36)

99 (39)

0.551

   No. of transfusions/patients*

6 ± 5.5

4.9 ± 4.1

0.412

  1. * Values presented as mean ± SD.
  2. † P values were determined wit the use of Student's t-test, the chi-square test or Fischer test as appropriate.
  3. ‡ Maximal dosage per day
  4. §Renal impairment: peak plasma creatinine > 2.5 mg/dl, Peak plasma urea nitrogen > 60 mg/dl, dialysis or continuous venovenous haemofiltration.